CN110636832A - 新制剂 - Google Patents

新制剂 Download PDF

Info

Publication number
CN110636832A
CN110636832A CN201880029092.2A CN201880029092A CN110636832A CN 110636832 A CN110636832 A CN 110636832A CN 201880029092 A CN201880029092 A CN 201880029092A CN 110636832 A CN110636832 A CN 110636832A
Authority
CN
China
Prior art keywords
formulation
formulation according
insulin
compound
zinc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880029092.2A
Other languages
English (en)
Chinese (zh)
Inventor
J·耶热克
D·格林
S·豪威尔
L·扎克热夫斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arecor Ltd
Original Assignee
Arecor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arecor Ltd filed Critical Arecor Ltd
Publication of CN110636832A publication Critical patent/CN110636832A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN201880029092.2A 2017-05-05 2018-05-03 新制剂 Pending CN110636832A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1707187.9 2017-05-05
GBGB1707187.9A GB201707187D0 (en) 2017-05-05 2017-05-05 Novel formulations
PCT/GB2018/051178 WO2018203060A2 (en) 2017-05-05 2018-05-03 Novel formulations

Publications (1)

Publication Number Publication Date
CN110636832A true CN110636832A (zh) 2019-12-31

Family

ID=59065623

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880029092.2A Pending CN110636832A (zh) 2017-05-05 2018-05-03 新制剂

Country Status (6)

Country Link
US (2) US20200093894A1 (enExample)
EP (1) EP3618804A2 (enExample)
JP (2) JP7534850B2 (enExample)
CN (1) CN110636832A (enExample)
GB (1) GB201707187D0 (enExample)
WO (1) WO2018203060A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
CA3094237A1 (en) 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
JP7465813B2 (ja) * 2018-04-04 2024-04-11 アレコル リミテッド インスリン化合物の送達のための医療用注入ポンプシステム

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006000A1 (en) * 2002-05-07 2004-01-08 Liselotte Langkjaer Novel formulations
US20080194461A1 (en) * 2006-06-23 2008-08-14 Aegis Therapeutics Llc Stabilizing Alkylglycoside Compositions and Methods Thereof
CN103249427A (zh) * 2010-12-14 2013-08-14 诺沃—诺迪斯克有限公司 速效胰岛素联合长效胰岛素
US20150273022A1 (en) * 2014-02-10 2015-10-01 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
ES2072596T3 (es) 1989-12-21 1995-07-16 Novo Nordisk As Preparaciones de insulina que contienen acido nicotinico o nicotinamida.
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US8173594B2 (en) 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
HUE027239T2 (en) 2009-06-26 2016-10-28 Novo Nordisk As Preparation containing insulin, nicotinamide and arginine
WO2012006283A1 (en) 2010-07-07 2012-01-12 Biodel Inc. Compositions and methods for modulating the pharmacokinetics and pharmacodynamics of insulin
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
WO2013186138A1 (en) * 2012-06-14 2013-12-19 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and arginine
TWI641381B (zh) * 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
WO2015106269A2 (en) * 2014-01-13 2015-07-16 Thermalin Diabetes, Llc Rapid action insulin formulations and pharmaceutical delivery systems
JO3624B1 (ar) 2014-05-08 2020-08-27 Lilly Co Eli تركيبات إنسولين سريعة المفعول
GB201607918D0 (en) * 2016-05-06 2016-06-22 Arecor Ltd Novel formulations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006000A1 (en) * 2002-05-07 2004-01-08 Liselotte Langkjaer Novel formulations
US20080194461A1 (en) * 2006-06-23 2008-08-14 Aegis Therapeutics Llc Stabilizing Alkylglycoside Compositions and Methods Thereof
CN103249427A (zh) * 2010-12-14 2013-08-14 诺沃—诺迪斯克有限公司 速效胰岛素联合长效胰岛素
US20130331320A1 (en) * 2010-12-14 2013-12-12 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
US20150273022A1 (en) * 2014-02-10 2015-10-01 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations

Also Published As

Publication number Publication date
WO2018203060A3 (en) 2018-12-13
WO2018203060A2 (en) 2018-11-08
GB201707187D0 (en) 2017-06-21
US20200093894A1 (en) 2020-03-26
JP2023071660A (ja) 2023-05-23
US20250268987A1 (en) 2025-08-28
EP3618804A2 (en) 2020-03-11
JP2020518636A (ja) 2020-06-25
JP7534850B2 (ja) 2024-08-15

Similar Documents

Publication Publication Date Title
US11278624B2 (en) Formulations
CA3034972C (en) A pharmaceutical insulin formulation
CN110582285B (zh) 稳定的胰岛素制剂
JP2023071660A (ja) 新規の製剤
WO2018203061A1 (en) Stable insulin formulations
CN111989088A (zh) 用于递送胰岛素化合物的医用输注泵系统
HK40013219B (en) Pharmaceutical formulation comprising an insulin compound

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination